EU and US could reach trade deal this weekend - Reuters
On Wednesday, William Blair analysts downgraded shares of Charles River Laboratories International Inc. (NYSE:CRL) stock from Outperform to Market Perform. The decision comes amid growing concerns about the company's near-term prospects, with the stock currently trading near its 52-week low of $160.84.
Despite these concerns, InvestingPro data shows the company maintains a "Good" overall financial health score and remains profitable with a healthy gross margin of 35.7%. Analysts at William Blair cited several headwinds facing Charles River, including the impact of the loss of exclusivity by large pharmaceutical companies, which are now expected to focus more on products closer to approval that can generate revenue in the near term.
The downgrade follows a period of optimism where sequential improvement in gross bookings and cancellations from large pharma during the third quarter of 2024 had suggested a potential rebound in investment in early-stage research and development (R&D).
This was anticipated to drive growth in Charles River's discovery and safety assessment (DSA) business in 2026. However, recent updates from the company, coupled with insights from a deep dive into large pharma, have cast doubt on this outcome.
Adding to the challenges, Charles River is facing softer pricing and increased uncertainty in its DSA business stemming from a recent recommendation by the Convention on International Trade in Endangered Species (CITES) to halt shipments of long-tailed macaques from Cambodia.
These primates are commonly used in research and development activities. Furthermore, headwinds in the company's contract development and manufacturing organization (CDMO) business, which was expected to be a significant contributor to margin expansion, are also of concern.
In light of these factors, William Blair analysts have adjusted their stance on Charles River Labs, indicating that the obstacles in the near term diminish the stock's appeal. The firm's downgrade reflects a cautious outlook for the company's performance in the face of these various challenges.
With the next earnings report due on February 12, 2025, investors should note that analysts maintain a consensus price target above current levels, suggesting potential upside despite near-term headwinds. For comprehensive analysis and real-time updates, visit InvestingPro, where you'll find additional exclusive insights and financial metrics.
In other recent news, Charles River Laboratories has been the subject of several analyst adjustments and notable developments. TD Cowen analysts have revised their outlook for the company, reducing the price target from $227 to $182 due to anticipated revenue pressures from the company's Discovery (NASDAQ:WBD) Services and Manufacturing Solutions segments.
This adjustment follows a preliminary guide suggesting continued declining performance into 2025. UBS analysts have also downgraded Charles River Labs due to anticipated mid-term sales growth pressures and uncertainty surrounding biotech funding for 2025.
Furthermore, a potential suspension of worldwide trade in wild monkeys from Cambodia—a key resource for the company—has raised concerns for Charles River Labs' revenue. Evercore ISI has noted that non-human primates are expected to contribute approximately $650 million to the company's revenue by 2025.
Jefferies analysts have revised the price target for Charles River Laboratories, reducing it in response to expected declines in organic revenue and challenges in the company's Microbial Solutions segment.
In addition, Citi analyst has reaffirmed a Sell rating on Charles River Laboratories, following the company's preliminary financial guidance for fiscal year 2025. The company anticipates a decline in organic revenues similar to that of fiscal year 2024, estimated at a 3-4% decrease. These recent developments provide a snapshot of the current state of Charles River Laboratories.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.